Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - Tambocor
Product / population
Selected adult maintenance-therapy initiation guidance, not a pill-in-the-pocket protocol.
Renal method
Both sources print indexed creatinine clearance, mL/min/1.73 m2
Source revision
Revision not established in selected retrieval
Retrieved
2026-09-10
Local review status
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Before use: Flecainide acetate - conventional oral tablets
Both sources print indexed CrCl. Do not silently replace it with an unindexed cutoff or combine this initiation schedule with acute conversion dosing.
What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.
GlobalRPh-hosted RX List · Selected adult maintenance-therapy initiation guidance, not a pill-in-the-pocket protocol.
Renal method: Both sources print indexed creatinine clearance, mL/min/1.73 m2 Source date: Revision not established in selected retrieval Retrieved: 2026-09-10
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Confirm the exact product, indication, renal measure and full source before prescribing.
Dialysis evidence: Removal information only - not a dialysis regimen
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Use frequent plasma-level monitoring in severe renal impairment. Increase cautiously only after levels plateau; a new steady state may take longer than 4 days.
Proarrhythmia, conduction disease, structural heart disease and interaction precautions require specialist assessment. Hemodialysis is not effective for removal; no replacement dose is inferred.
Flecainide - source renal initial dosing
Printed indexed CrCl, mL/min/1.73 m2
Source-specific dose / instruction
<=35
100 mg once daily OR 50 mg twice daily
Less severe renal disease
100 mg every 12 hours
Read the retained text before reformatting
Flecainide - source renal initial dosing
Printed indexed CrCl, mL/min/1.73 m2
Source-specific dose / instruction
<=35
100 mg once daily OR 50 mg twice daily
Less severe renal disease
100 mg every 12 hours
Use frequent plasma-level monitoring in severe renal impairment. Increase cautiously only after levels plateau; a new steady state may take longer than 4 days.
Proarrhythmia, conduction disease, structural heart disease and interaction precautions require specialist assessment. Hemodialysis is not effective for removal; no replacement dose is inferred.
Use frequent plasma-level monitoring in severe renal impairment. Increase cautiously only after levels plateau; a new steady state may take longer than 4 days.
Proarrhythmia, conduction disease, structural heart disease and interaction precautions require specialist assessment. Hemodialysis is not effective for removal; no replacement dose is inferred.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.